Partial gland ablation outcomes for localized prostate cancer in patients with MRI-visible and MRI-invisible lesions. This is an ASCO Meeting Abstract from the 2023 ASCO Genitourinary Cancers ...
Patients who undergo single-port robotic prostate or kidney surgery tend to have less blood loss and postoperative pain and shorter hospital stays compared with patients undergoing multi-port robotic ...
3D augmented reality-assisted imaging during RARP enabled precise identification and removal of tumor lesions at the level of preserved neurovascular bundles, which may reduce positive surgical ...
Short term pathologic outcomes and biochemical recurrence rates of single port transvesical retzius-sparing radical prostatectomy as compared to multiport radical prostatectomy. This is an ASCO ...
The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy ...
Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...
Prostate cancer is the most common malignant tumor in men, accounting for 29% of male neoplasm diagnoses in the United States alone. Radical prostatectomy remains the preferred treatment for localized ...
SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...
No significant improvement seen in overall survival with addition of hormone therapy to post-radical prostatectomy radiotherapy.
Urologic surgeon Jose M. Flores, MD is lead author of a new study investigating the risk of biochemical recurrence after radical prostatectomy when taking ED drugs. There have been conflicting studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results